HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review

BMC Infectious Diseases

Shijun Chen¹  Shumin Ma¹  Shaolei Han¹  Zhaomin Zheng¹  Wenjun Du¹ 

[1] Department of Liver Disease, Jinan Infectious Disease Hospital, Shandong University School of Medicine, 22029# Jing-Shi Road, Jinan 250021, China

关键词: Prednisone;    Occult HBV infection;    IgM nephropathy;    Hepatitis B virus reactivation;   

Others  :  1145933
DOI  :  10.1186/1471-2334-13-394

 received in 2013-05-28, accepted in 2013-08-21,  发布年份 2013

【 摘 要 】

Background

Reactivation of hepatitis B virus (HBV), characterized by increased levels of serum HBV DNA, abnormal liver function and hepatic failure, is a frequent complication of immunosuppressive therapy and chemotherapy in patients with HBV infection. However, reactivation of occult HBV infection with immunosuppressive therapy or chemotherapy is rare.

Case presentation

A 77-year-old man was diagnosed with nephrotic syndrome and IgM nephropathy with unclear pathogenesis. Liver function was normal, HBV-related serum markers were negative and HBV DNA titer was below the upper limits of normal. Two months following the start of prednisone therapy for his nephrotic syndrome, laboratory tests revealed a substantial increase in serum transaminase levels (ALT: 490 IU/L; AST: 149 IU/L) and an elevation of HBV DNA level (3.42×10⁶ copies/ml). We tested stored kidney tissue for HBsAg and HBcAg using immunohistochemistry and found the sample to be HBcAg positive, allowing us to confirm the etiology of nephropathy as an occult HBV infection. The cause of the hepatitis was thought to be HBV reactivation, so we immediately administered lamivudine. One month after the initiation of daily lamivudine treatment, laboratory tests revealed that serum levels of transaminases had improved (ALT: 35 IU/L; AST: 17 IU/L). Patient examination one year later showed that HBeAg had decreased with a concomitant increase of HBeAb, the quantity of HBV DNA was undetectable, and liver function and renal function had stabilized.

Conclusion

This is the first report describing HBV reactivation in an occult HBV infection patient treated with oral prednisone for nephrotic syndrome. HBV-associated antigen should be regularly tested for in patients with unknown etiological glomerulonephritis in areas with high HBV viral popular and even in those with no clinical evidence for diagnosis of HBV.

【 授权许可】

   
2013 Du et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Knieser MR, Jenis EH, Lowenthal DT, Bancroft WH, Burns W, Shalhoub R: Pathogenesis of renal disease associated with viral hepatitis. Arch Pathol 1974, 97(4):193-200.
• [2]Brzosko WJ, Krawczynski K, Nazarewicz T, Morzycka M, Nowoslawski A: Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet 1974, 2(7879):477-482.
• [3]Levy M, Gagnadoux MF: Membranous nephropathy following perinatal transmission of hepatitis B virus infection—long-term follow-up study. Pediatr Nephrol 1996, 10(1):76-78.
• [4]Wiggelinkhuizen J, Sinclair-Smith C, Stannard LM, Smuts H: Hepatitis B virus associated membranous glomerulonephritis. Arch Dis Child 1983, 58(7):488-496.
• [5]Venkataseshan VS, Lieberman K, Kim DU, et al.: Hepatitis-B-associated glomerulonephritis: pathology,pathogenesis, and clinical course. Medicine (Baltimore) 1990, 69(4):200-216.
• [6]Lin CY: Treatment of hepatitis B virus-associated membranous nephropathy with recombinant alphainterferon. Kidney Int 1995, 47(1):225-230.
• [7]Willson RA: Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol 1997, 92(1):3-17.
• [8]Fang LJ, Sheng FY, Guo YQ, et al.: Hepatitis B virus associated nephritis in adults and children. ZhonghuaChuanranbingxueZazhi 1996, 14:92-95.
• [9]Raimondo G, Pollicino T, Cacciola I, Squadrito G: Occult hepatitis B virus infection. J Hepatol 2007, 46:160-170.
• [10]Jeantet D, Chemin I, Mandrand B, Tran A, Zoulim F, Merle P, Trepo C, Kay A: Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004, 73:508-515.
• [11]Garfein RS, Bower WA, Loney CM, Hutin YJ, Xia GL, Jawanda J, Groom AV, Nainan OV, Murphy JS, Bell BP: Factors associated with fulminant liver failure during an outbreak among injection drug users with acute hepatitis B. Hepatology 2004, 40:865-873.
• [12]Petzold DR, Tautz B, Wolf F, Drescher J: Infection chains and evolution rates of hepatitis B virus in cardiac transplant recipients infected nosocomially. J Med Virol 1999, 58:1-10.
• [13]Zhou XJ, Laszik Z, Nadasdy T, D’Agati VD, Silva FG: Silva’s diadnostic renal pathology. Kidney International 2010, 77:939-940.
• [14]Liang TJ, Hasegawa K, Rimon N, Wands JR, Ben-Porath E: A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med 1991, 324:1705-1709.
• [15]Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G: Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
• [16]Lai KN, Lai FM, Tam JS, Vallance-Owen J: Strong association between IgA nephropathy and hepatitis B surface antigenemia in endemic areas. Clin Nephrol 1988, 29(5):229-234.